Kidney Week

Abstract: TH-PO0734

In Vitro Characterization of a Novel Hemofilter for Acute Kidney Care

Session Information

• AKI: Critical Care, CKRT, Cardiorenal Syndromes, and Clinical Outcomes
  October 22, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

• 102 AKI: Clinical, Outcomes, and Trials

Authors

• Zawada, Adam M., Fresenius Medical Care Deutschland GmbH, Sankt Wendel, Germany, Germany

Adam M. Zawada, PhD

• Theis, Lukas, Fresenius Medical Care Deutschland GmbH, Sankt Wendel, Germany, Germany

Lukas Theis

• Nitschel, Robert, Fresenius Medical Care Deutschland GmbH, Sankt Wendel, Germany, Germany

Robert Nitschel, MSc

• Emal, Karlee, Fresenius Medical Care, Ogden, Utah, United States

Karlee Emal, MHA

• Pohlmeier, Robert, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany

Robert Pohlmeier, DrMed

• Boyington, Skyler, Fresenius Medical Care, Ogden, Utah, United States

Skyler Boyington

• Erlenkoetter, Ansgar, Fresenius Medical Care Deutschland GmbH, Sankt Wendel, Germany, Germany

Ansgar Erlenkoetter, PhD

Background

Hemofilters combining high performance with good hemocompatibility are key components in the treatment of patients with acute kidney failure. The novel multiFlux hemofilter features a polysulfone membrane with increased hydrophilicity to reduce protein fouling, aiming to increase performance stability and hemocompatibility. In the present study, we compared the multiFlux hemofilter to filters currently used in clinical practice.

Methods

Filter performance was characterized by determining urea, creatinine and β2-microglobulin (β2M) dialysate-side plasma clearance over 24h at Q_B=100ml/min, Q_D=33ml/min, Q_F=17ml/min. For hemocompatibility, a blood recirculation setup was used to characterize platelet activation (platelet counts, β-thromboglobulin [β-TG]), plasmatic coagulation (thrombin–antithrombin III complex [TAT], activated clotting time [ACT]), complement activation (complement factor sC5b-9), and leukocyte activation (polymorphonuclear neutrophil [PMN] elastase). The multiFlux was compared to Ultraflux AV (UF; both polysulfone-based, Fresenius Medical Care), Prismaflex HF (HF, polyarylethersulfone-based) and Prismaflex ST (ST, AN69ST-based; both Vantive).

Results

All filters reached a urea and creatinine clearance at the effluent limit (~50ml/min). Adsorption effects of the AN69ST membrane interfered with β2M clearance and hemocompatibility assessments, precluding meaningful comparisons with the other filters. Among the poly(arlyether)sulfone-based dialyzers, multiFlux showed the highest β2M clearance over 24h (35.1±2.1ml/min, UF: 21.5±4.0ml/min, HF: 22.3±3.8ml/min, p<0.001 for both comparisons). Moreover, in comparison to UF and HF, multiFlux showed significantly lower platelet count reduction (p<0.05 and p<0.01, respectively) and sC5b-9 increase (p<0.05 for both), as well as significantly lower β-TG increase (p<0.05) and ACT decrease as compared to UF (p<0.05).

Conclusion

The novel multiFlux hemofilter demonstrated the highest middle-molecule clearance and a favorable hemocompatibility profile among poly(arlyether)sulfone-based dialyzers, especially with regards to platelet and complement activation. This in vitro study supports previous findings that increased membrane hydrophilicity improves performance and hemocompatibility and underscores the need for critical interpretation of results when different membrane types – especially those with strong adsorption characteristics – are compared in such test settings.

Funding

• Commercial Support – Fresenius Medical Care